Malignant Central Nervous System Neoplasm

Malignant Central Nervous System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

2,864 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 822
Recruiting: 449
Ph III recruiting: 27
Growth YoY: +21.1%
Industry share: 16%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.9%
Trials / 1,000 deaths: 45.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (419)

clinicaltrialsPublishedShowing 51–100 of 1,139 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07644312	Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG	not yet recruiting	Phase 2	12	Nationwide Children's HospitalOTHER	0	Sep 9, 2026	clinicaltrials
NCT03952598	Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy	suspended	Phase 2	42	National Cancer Institute (NCI)NIH	1	Sep 8, 2026	clinicaltrials